Skip to main content
SpringerLink
Log in

Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial

  • Perspective
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jesperson CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish-population based cohort study. Eur Urol. 2014;65:704.

    Article  Google Scholar 

  2. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials androgen deprivation. JAMA. 2011;306:2359. 299:289-95

    Article  CAS  Google Scholar 

  3. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565.

    Article  CAS  Google Scholar 

  4. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Eng J Med. 2020;382:2187–96.

    Article  CAS  Google Scholar 

  5. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, SØrensen PS, et al. Cardiovascular safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation 2021;144:1295–307.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, University of Toronto, Toronto, ON, Canada

    Raj Tiwari, Katherine Lajkosz, Neil Fleshner & Christopher J. D. Wallis

Authors
  1. Raj Tiwari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine Lajkosz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil Fleshner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christopher J. D. Wallis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

RT: Project development, paper writing. KL: Data management, data analysis. NF: Project development, paper editing. CJDW: Project development, paper editing.

Corresponding author

Correspondence to Raj Tiwari.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tiwari, R., Lajkosz, K., Fleshner, N. et al. Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. Prostate Cancer Prostatic Dis 25, 657–658 (2022). https://doi.org/10.1038/s41391-021-00483-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-021-00483-5

  • Springer Nature Limited

Search

Navigation